Enlicitide Slashes LDL-C by 57.1% in Major Clinical Trial

Enlicitide, a new oral medication, has demonstrated significant efficacy in lowering LDL-C levels, according to findings from the CORALreef Lipids trial. The study, which enrolled 2,909 patients, found that those taking enlicitide experienced a mean reduction of 57.1% in LDL-C over 24 weeks, compared to just 3% in the placebo group. Secondary endpoints, including non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) levels, also showed statistically significant improvements.

Despite these promising results, the trial was not designed to assess cardiovascular outcomes directly. Enlicitide is currently approved by the FDA only as an adjunct therapy to statins for lowering lipid levels. Further research is needed to determine its potential cardio-protective benefits when used alone.

To address this, Merck is conducting the phase 3 CORALreef Outcomes trial, which aims to evaluate enlicitide's effectiveness in reducing major adverse cardiovascular events. This study is expected to conclude in November 2029.

Healthcare professionals emphasize that enlicitide is intended to complement statins rather than replace them. As ongoing research continues, the potential for enlicitide to enhance cholesterol management and improve patient outcomes remains a key focus in cardiovascular medicine.